Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silence Therapeutics Plc ADR (NQ: SLN ) 18.20 -0.03 (-0.16%) Streaming Delayed Price Updated: 1:49 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Silence Therapeutics Plc ADR < Previous 1 2 3 4 Next > Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday January 31, 2024 U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From Silence Therapeutics plc Via Business Wire 12 Health Care Stocks Moving In Wednesday's Intraday Session December 13, 2023 Via Benzinga Where Silence Therapeutics Stands With Analysts August 17, 2023 Via Benzinga What 6 Analyst Ratings Have To Say About Silence Therapeutics June 26, 2023 Via Benzinga The Latest Analyst Ratings for Silence Therapeutics May 11, 2023 Via Benzinga Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments December 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results November 14, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Present at Jefferies London Healthcare Conference November 08, 2023 From Silence Therapeutics plc Via Business Wire Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate November 01, 2023 Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session November 01, 2023 Via Benzinga Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease November 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference September 26, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in September Investor Conferences September 06, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports Second Quarter 2023 Results August 16, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration July 11, 2023 From Silence Therapeutics plc Via Business Wire Earnings Scheduled For August 10, 2023 August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. Via Benzinga Silence Therapeutics to Present at the Jefferies Healthcare Conference May 31, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports First Quarter 2023 Results May 16, 2023 From Silence Therapeutics plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 May 08, 2023 Via Benzinga Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration May 04, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events May 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference April 25, 2023 From Silence Therapeutics plc Via Business Wire Stocks That Hit 52-Week Lows On Tuesday April 25, 2023 Tuesday's session saw 286 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Monday April 24, 2023 On Monday, 147 stocks made new 52-week lows. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 17, 2023 Via Benzinga Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera April 04, 2023 From Silence Therapeutics plc Via Business Wire Stocks That Hit 52-Week Lows On Friday April 21, 2023 During Friday's session, 149 stocks hit new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Wednesday March 29, 2023 On Wednesday, 81 companies hit new 52-week lows. Via Benzinga Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days March 29, 2023 From Silence Therapeutics plc Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.